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Introduction
Schizophrenia (SCZ) can be a chronic, debilitating psychiatric 
disorder; it affects approximately 1% of the adult population (1). 
Neuroimaging has consistently demonstrated widespread struc-
tural and functional brain abnormalities (2–5). Unaffected fam-
ily members and twins of patients, in some cases, show subtle 
abnormalities in brain structure and function (6), supporting the 
theory that genetic factors play a major role in the development 
of the disorder. Numerous genome-wide studies have identified 
regions of the genome that harbor risk genes for SCZ (7, 8). These 
effects are often small and can be difficult to interpret biologi-
cally; individually, their downstream effects may reveal relatively 
little about the mechanistic basis of SCZ. In contrast, rare, highly 
penetrant variants account for a small fraction of the liability 
— but their high correlation with the disease phenotype makes 
these mutations ideal as potential models of SCZ. The disrupted 
in schizophrenia 1 (DISC1) gene locus is a particular case. DISC1 
was originally identified in a large Scottish family (9), spanning 
the chromosome 1 breakpoint of balanced chromosomal trans-
location t(1;11)(q42.1;q14.3) (10). A majority of the family mem-
bers with this chromosomal abnormality have a heavy burden 
of major psychiatric disorders, but no physical, neurological, or 
dysmorphic conditions (11). The involvement of the DISC1 path-
way in psychiatric disorders has since been reported in genetic 
association studies within different pedigrees and more diverse 
populations (12–17). DISC1 continues to feature strongly when 
considering genome-wide associations in terms of gene networks 
or in combination with biological function (18–20). However, 
large-scale genome-wide approaches have not identified a clear 
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patients from the SCZ group had complete quality controlled 
data. We manually selected 24 participants from the HC group to 
match the 24 patients in the SCZ group for age and sex in a pair-
wise fashion (Table 1). For the family cohort of translocation car-
riers (T+) (n = 12) and noncarriers (T–) (n = 18), all 30 participants’ 
data passed quality control. Similarly, all data from patients 
recruited with bipolar disorder type I (BP) passed quality control.
DISC1 translocation and SCZ. Each participant in the T+ group 
had a psychiatric diagnosis with varying degrees of severity and a 
range of DSM-IV categories (Table 2). Diagnoses included major 
depression, psychosis phenotypes (SCZ and schizoaffective), and 
bipolar phenotypes (BP and cyclothymia). Three of the 18 family 
members without the translocation had a history of depression, 
but none were suffering from a current mental disorder.
Statistically significant performance was found for 3 of the 
imaging measures: cortical surface area (AUC, 0.71; accuracy, 
66.7%; P < 0.005), cortical thickness (AUC, 0.70; accuracy, 
68.8%; P < 0.005 by permutation), and regional cerebral blood 
flow (rCBF) (AUC, 0.82; accuracy, 77.1%; P < 0.001). The model 
trained on the subcortical volumes did not reach significance. 
No statistically significant correlation was observed between the 
predictive probabilities of belonging to the SCZ group and dose 
of antipsychotic medication, as estimated by the chlorpromazine 
equivalents. The brain regions driving the model are visualized 
as weights displayed on the cortical surface in Figure 1A. These 
weights are all less than zero, which suggests widespread thinning 
of the cortex in the SCZ group. This is confirmed by data shown in 
Figure 1B, where we show that cortical thickness in both the left 
and right hemispheres is significantly reduced in the SCZ group 
when compared with the HC group (all 4 groups were matched 
for age and sex). Qualitatively, we note that the temporal lobe and 
precentral gyrus are strongly weighted regions.
The translocation family members were then used as a test 
set for the 3 successful models (see Table 1 for the subject charac-
teristics of the family members). The results are displayed as con-
tingency tables in Figure 2. For cortical thickness, 72.2% (13/18) 
of the T– group were classified as belonging to the HC group and 
83.3% (10/12) of the T+ group were classified as belonging to the 
SCZ group (P < 0.01). For cortical surface area, 66.7% (12/18) of 
the T– group were classified as belonging to the HC group and 
association between DISC1 locus variants and SCZ (7). Therefore, 
although still of considerable interest for psychiatry, the status of 
DISC1 as a risk factor for SCZ has been debated (21, 22).
The most commonly reported neurobiological phenotypes 
in animal models with mutations at DISC1 are enlarged ven-
tricles (23–26), cortical thinning (23), reduced cortical volume 
(25), reduction in parvalbumin GABAergic neurons (24, 25), 
and behavioral changes that together are suggestive of SCZ-like 
phenotypes (23–26). The brain-related phenotype in humans 
has been studied in the context of SNPs within DISC1. Cannon 
et al. (27) found that haplotype blocks of SNP markers spanning 
the DISC1 and translin-associated factor X genes were associ-
ated with reduced gray matter density in the prefrontal cortex 
as well as several quantitative endophenotypic traits previously 
observed to covary with SCZ. Brauns et al. (28) examined the 
effect of DISC1 SNPs on brain structure and function in healthy 
volunteers. For a particular SNP, they reported reduced cortical 
thickness in the left supramarginal gyrus. Carless et al. (29) inves-
tigated the brain-related phenotype in a large pedigreed cohort. 
They reported that variations in DISC1 were most significantly 
associated with cortical thinning in regions often implicated in 
psychiatric disorders (30–32). Callicott et al. (33) used functional 
neuroimaging to show that an interaction between DISC1 and 
GABA signaling via SLC12A2 has demonstrable effects on adult 
human hippocampal area function in vivo.
Here, we investigated whether members of the original Scot-
tish family carrying the DISC1 translocation have a common brain-
related phenotype. Based on studies in experimental animals and 
humans, we expected widespread reductions in cortical thickness 
in DISC1 translocation carriers. Importantly, we investigated how 
similar the neurophenotype is to what we observe in patients with 
SCZ using multivariate pattern recognition techniques (34). This 
methodology enabled us to train a model to separate healthy con-
trols (HC) and patients and to apply this model to translocation 
carriers and noncarriers.
Results
Participants. Following quality control of the imaging data, 5 par-
ticipants from the group of patients diagnosed with SCZ and 1 
participant from the group of HC were excluded. Therefore, 24 
Table 1. Subject characteristics
HC SCZ T+ T– T–ʹ
n 24 24 12 18 14
Age (yr; mean ± SD) 38.4 ± 10.9 38.5 ± 12.1 53.9 ± 16.3 37.9 ± 20.34 43.6 ± 19.6
Sex 17 M, 7 F 17 M, 7 F 6 M, 6 F 11 M, 7 F 8 M, 6 F
PANSS total score 31.7 ± 4.7 52.7 ± 17.98 49.1 ± 25.7 32.7 ± 5.2 33.5 ± 5.2
PANSS negative score 7.1 ± 0.3 13.2 ± 6.4 10.4 ± 10.2 7 ± 0 7 ± 0
PANSS positive score 7.2 ± 0.6 12.8 ± 5.6 11.0 ± 6.9 7 ± 0 7 ± 0
PANSS general score 17.4 ± 4.5 28.0 ± 9.1 29.5 ± 10.8 19.5 ± 7.1 20.5 ± 7.1
Antipsychotic dose (chlorpromazine 
equivalents, mg)
0 ± 0 445.9 ± 408.6A 109.1 ± 242.7B 0 ± 0 0 ± 0
HC and SCZ patients were age and sex matched. Values presented are mean ± SD. AFive patients were not medicated at the time of scanning. BOnly 2 
subjects were medicated at the time of scanning, with a chlorpromazine equivalent of 600 mg per participant.
Downloaded from http://www.jci.org on November 11, 2015.   http://dx.doi.org/10.1172/JCI82636
The Journal of Clinical Investigation C l i n i C a l  M e d i C i n e
3 7 1 6 jci.org   Volume 125   Number 9   September 2015
the HC versus SCZ on a group of patients diagnosed with BP (age, 
43.4 ± 13.2 years; sex, 13 M, 7 F). We found that 45% of bipolar 
patients were classified as belonging to the SCZ group and 55% 
were classified as belonging to the HC group (P > 0.05).
Discussion
Here, we explore the brain-related phenotype of a balanced 
translocation at DISC1 in the original Scottish family in which 
this genetic mutation was discovered. We focused on measures 
of brain structure and perfusion — cortical surface area, cortical 
thickness, subcortical volumes, and rCBF. Using 2 complimentary 
analyses, we found that cortical thickness was significantly asso-
ciated with a balanced translocation at DISC1. First, members of 
the same family with and without the DISC1 translocation could 
be discriminated based on cortical thickness. Second, the patients 
diagnosed with SCZ and those carrying the DISC1 translocation 
shared a similar pattern of cortical thickness despite the heteroge-
neous clinical phenotype observed in the carriers, which included 
bipolar phenotypes, recurrent depression, and SCZ. This pleio-
tropic property of variation at DISC1 has been widely reported in 
other studies as well as within the pedigree studied in this work 
(10, 11). The cortical surface area and rCBF were not sensitive to 
translocation at DISC1, suggesting that the cortical thickness phe-
notype represents a more specific feature that is shared by SCZ 
and variation at DISC1.
We observed widespread reductions in cortical thickness in the 
SCZ and T+ groups (Figure 1; all 4 groups were matched for age 
and sex) in a pattern similar to that reported by Carless et al. (29) 
related to common variants in the DISC1 genotype. Reductions in 
regional cortical thickness have been reported in psychiatric con-
ditions linked to DISC1, namely SCZ (37, 38), BP (32), and major 
depressive disorder (MDD) (39). Studies investigating subjects at 
ultrahigh risk (30) and those whose relatives suffered from either 
depression (32) or SCZ (40) also report changes in cortical thick-
ness despite the absence of the clinical phenotype. Translocation 
carriers were also found to have significantly reduced P300 ampli-
tude and latency in a manner similar to subjects with SCZ but 
distinct from that of family members who do not carry the trans-
location and control subjects (11). Therefore, carriers were found 
to resemble patients diagnosed with SCZ even though several of 
the carriers had no psychiatric diagnosis. This indicates that inheri-
tance of the translocation results in consistent disturbances in 
brain function, which may not always cosegregate with psychiatric 
diagnosis. As an example, we found that the discriminative model 
58% (7/12) of the T+ group were classified as belonging to the SCZ 
group (P > 0.05). For the rCBF, 81% (13/16) of T– group were clas-
sified as belonging to the HC group and 45% (5/11) of the T+ group 
were classified as belonging to the SCZ group (P > 0.05).
In Figure 3A, the predictive probabilities of belonging to the 
SCZ group (P[SCZ]) are plotted against the mean cortical thick-
ness. A strong negative correlation can be observed (Pearson’s 
rho, –0.86; P < 0.00001), indicating that reduced cortical thick-
ness is associated with an increased probability of belonging to 
the SCZ group and, as in Figure 1B, we observed lower cortical 
thickness in the carriers. In Figure 3B, the mean cortical thick-
ness, P(SCZ), and clinical diagnosis are displayed on an individ-
ual basis for the T+ group.
The correlation coefficient (Pearson’s rho) between the PANSS 
General Psychopathology scale (35) of the predictive probabilities 
was 0.52 (P = 0.0149) and following the exclusion of outliers using 
the Cook distance (36) was 0.45 (P = 0.0149). Considering the trans-
location positive group only, the correlation coefficient was 0.57 (P 
= 0.052) and following the exclusion of outliers was 0.47 (P = 0.14). 
The predictive probabilities of belonging to the SCZ group were not 
correlated with age or the estimated total intracranial volume.
DISC1 translocation carriers versus noncarriers. The T– and T+ 
groups were then compared directly. As the data are now used to 
train the model, we selected 14 participants from the T– group to 
match the T+ group for age and sex. The participants formed the 
group known as T–ʹ. The classification performance can be seen in 
Table 3. For cortical thickness, an AUC of 0.75 and corresponding 
accuracy of 73% were achieved, with significance at P < 0.01.
Specificity of the cortical thickness phenotype. To assess the mod-
el of cortical thickness in terms of its disease specificity, we tested 
Table 2. Lifetime diagnoses for family members with and 
without the t1:11 translocation
T+ T–
SCZ/schizoaffective 2 0
Bipolar affective disorder 1 0
Recurrent MDD/bipolar NOS 3 1
Single-episode MDD 2 2
Cyclothymia 3 0
Adolescent conduct disorder 1 0
NOS, not otherwise specified.
Table 3. Performance of classification techniques in discriminating between age- and sex-matched noncarriers and carriers of the 
translocation
Modality n AUC Accuracy Sensitivity Specificity
Cortical surface area 26 0.65 57.7% 58.3% 57.1%
Cortical thickness 26 0.75 73.2%A 75.0% 71.4%
Subcortical volume 26 0.65 61.90% 66.7% 57.1%
ASL 22 0.36 50% 45.5% 54.6%
ASL, arterial spin labeling images. AUC was extracted from the receiver operator characteristic. n indicates total number of subjects across both groups.  
AP <0.01, by permutation.
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DISC1 results in neuropathological and behavioral changes that 
are reminiscent of (but not limited to) the findings in major psy-
chiatric disorders, in particular, SCZ (41). Overall, these studies 
add to the accumulating evidence that DISC1 plays an important 
role in cortical genesis. To date, these animal studies have pro-
vided qualitative links between variations at DISC1 and SCZ. Our 
work represents one of the first studies to quantitatively compare 
the abnormalities in brain structure and function due to variation 
at DISC1 to those abnormalities associated with SCZ. We confirm 
that the pattern of cortical thinning observed in carriers of the 
translocation is highly similar to that observed in the SCZ group, 
whereas rCBF and cortical surface area do not share a common 
pattern of abnormalities.
One caveat of this study is the possible effect of medica-
tion. For the SCZ group, all but 5 subjects were medicated at the 
time of scanning. Given that the patients in the SCZ group were 
receiving different combinations of medications (mood stabiliz-
ers, antipsychotics, antidepressants, etc.) that could have differ-
ential effects on the brain, we do not expect the effect of medi-
cation to have driven the classification between HC and SCZ. 
Certainly, the predictive probabilities of belonging to the SCZ 
group did not correlate with the level of medication, as measured 
by chlorpromazine equivalents. Finally, members of the trans-
location carrier group that were identified as having a cortical 
of cortical thickness for HC versus SCZ was not sensitive to the BP 
in a clinical cohort. However, the subset of translocation carriers 
with bipolar phenotypes was indeed classified as belonging to the 
SCZ group (see Figure 3B) and the 2 carriers who were classified 
as HC both had a clinical diagnosis of single-episode MDD. These 
findings together with our data support the hypothesis that varia-
tion in DISC1 affects the normal spectrum of brain development 
and function, producing some features that are redolent of SCZ 
but are not representative of a phenocopy of the disorder. Further-
more, our data indicate that the consistency in the cortical thick-
ness phenotype of translocation at DISC1 does not simply translate 
to a consistent clinical phenotype, which is likely to be dependent 
on other factors, whether genetic and/or environmental.
The role of DISC1 has also been studied using animal mod-
els of disruption at this locus. Transgenic DISC1 mice have been 
developed using different approaches and experimental para-
digms (23–26). These studies reported enlarged lateral ventricles 
(23, 24, 26), reduced cerebral cortex (25) and the thinning of lay-
ers II/III (23), reduction in parvalbumin neurons (23, 24), and 
attenuation of neurite outgrowth in the cortex (23, 26) as well as 
behavioral changes. Ayhan et al. reported that a mouse model of 
mutant DISC1 has differential effects across various stages of neu-
rodevelopment (prenatal, postnatal, and both) (25). These stud-
ies have reported consistent findings indicating that mutation at 
Figure 1. Pattern of corti-
cal thickness across the 
groups. (A) Surface-based 
weight map showing the 
multivariate weights for 
the model discriminating 
between the HC (label –1) 
and the patients diagnosed 
with SCZ (label +1). (B) 
Box plot displaying corti-
cal thickness across both 
hemispheres and across the 
4 groups. *P < 0.05. Note 
that all 4 groups were age 
and sex matched for this 
comparison.
Downloaded from http://www.jci.org on November 11, 2015.   http://dx.doi.org/10.1172/JCI82636
The Journal of Clinical Investigation C l i n i C a l  M e d i C i n e
3 7 1 8 jci.org   Volume 125   Number 9   September 2015
Methods
Participants. Twenty-nine patients diagnosed with 
SCZ and 19 patients diagnosed with BP were recruit-
ed. Forty-one HC were recruited. Thirty participants 
were recruited from a previously reported Scottish 
family (9–11). Karyotyping using a custom PCR meth-
od (42, 43) was used to identify the presence of the 
translocation in 12 family members (translocation-
positive group [T+]) and absence in 18 family mem-
bers (translocation-negative group [T–]).
PCR typing of translocation breakpoint. The trans-
location status of all participants was tested on new 
blood samples using PCR-based methods. Primers 
were designed to span the t(1;11) breakpoint (44), using the Primer 
3 primer design program (42, 43). The translocation primers were as 
follows: t1;11_chr1TTTCTTTGGAAGGCACCTTATC, t1;11_Chr11AG-
CAAAGTGGGTGAAGAATAGAG (PCR product size, 1105 bp). DNA 
was coamplified in the same reaction using DISC1 exon 9 primers 
(DISC1, Ex9f TTCCCCAGAGGACTGCTAAG; DISC1, Ex9r AAAT-
GTCCCCAAGGAAAAGG, PCR product size, 484 bp) to verify the 
assay function. PCR was performed in a total volume of 10 μl with 20 
ng DNA, 1× reaction buffer with 1.5 mM MgCl2 (PerkinElmer), 100 μM 
of each dNTP (Peqlab), 0.5 U Taq DNA polymerase (Sigma-Aldrich), 
and 0.33 μM of each primer (Sigma-Aldrich). PCR cycling was carried 
out on a PTC-225 thermal cycler (MJ Research). PCR cycling condi-
tions consisted of denaturation at 95°C for 1 minute, followed by 10 
cycles of 93°C for 20 seconds, 70°C for 30 seconds, minus 1°C/cycle 
and 72°C for 1 minute, followed by 30 cycles of 93°C for 20 seconds, 
60°C for 30 seconds and 72°C for 1 minute, and a final extension of 
72°C for 10 minutes. Five microliters of the PCR product was resolved 
on a 1.5% agarose gel, and PCR product size was estimated against 
250 ng of λ HindIII size standard (Life Technologies).
Clinical assessment. Clinical diagnoses of all participants were 
established during face-to-face interviews conducted by a consultant 
psychiatrist using the structured clinical interview for DSM-IV (SCID) 
(45). Life-time diagnoses, according to DSM-IV criteria, were reached 
by consensus between 2 psychiatrists. If there was any disagreement 
in diagnosis, then this was resolved on discussion with the senior clini-
cal researcher (S.M. Lawrie). These diagnoses were based on the inter-
views and supplemented, where appropriate, by inspection of hospital 
case records, collateral information from relatives and carers, and 
clinical data collected at the time of previous follow-up contacts. Par-
ticipants were further assessed using the PANSS questionnaires (46). 
Symptom ratings took place within 1 week of the MRI acquisition.
Neuroimaging. Brain imaging was performed at the Clinical 
Research Imaging Centre (http://www.cric.ed.ac.uk/). The radiogra-
pher who performed the acquisition was not made aware of the clini-
cal or genetic status of the participants. Imaging was performed on a 
Siemens Verio 3T scanner using the matrix head coil with 12 elements. 
A structural brain image was acquired using a T1-weighted magnetiza-
tion prepared rapid acquisition gradient echo sequence prescribed par-
allel to the AC-PC line with repetition time (TR) = 2300 ms, echo time 
(TE) = 2.98 ms, inversion time (TI) = 900 ms, and flip angle = 9°, yield-
ing 160 contiguous 1-mm slices of 256 × 256 voxels. Perfusion imag-
ing was performed to quantify rCBF using the PICORE Q2TIPS pulsed 
arterial spin labeling sequence (22 slices, TR = 3000 ms, TE = 14 ms, 
TI1 = 700 ms, T1-stop = 1400 ms, and TI2 = 1600 ms).
thickness phenotype similar to that of the SCZ group were mostly 
medication free, with only 2 subjects medicated with both mood 
stabilizers and antipsychotics.
Another consideration is the specificity of the model trained 
to discriminate between the HC and SCZ groups. It is possible 
that the classification may be driven by nonspecific features 
related to comparing healthy with nonhealthy participants. How-
ever, for the model to perform with high sensitivity (i.e., accurate 
classification of those with SCZ), a consistent pattern of brain 
changes would need to be identified in the SCZ group; as this is 
the case reported here, we conclude that a shared pattern of brain 
changes is present in the SCZ group. To assess the specificity of 
the cortical thickness phenotype, we tested the HC versus SCZ in 
a group of patients diagnosed with BP. The BP group was random-
ly assigned to the HC and SCZ group, implying that the classifier 
is not merely a model of disease versus health but is specific to 
the pattern of cortical thinning in SCZ. We speculate that this may 
be because patients with BP have a lesser developmental compo-
nent to their adult brain structure. A longitudinal study would be 
required to fully realize the role of development in the cortical 
thickness phenotype we demonstrate here. It would also be inter-
esting to understand the results presented here in the context of 
MDD, which has been diagnosed in 5 of the T+ group (3 of which 
have a recurrent diagnosis) and 3 of the T– group (1 recurrent). 
These data could enable a richer description of the brain-related 
phenotype of variation at DISC1.
The sample size for the family is modest, which is to be 
expected given that we were limited to members of the original 
Scottish family. We believe that the uniqueness of this cohort 
serves to compensate for the modest sample size. Importantly, 
our methodology enables us to test individual family members 
using models trained with either the HC and SCZ groups or the 
family data directly.
Although implicated as a risk factor for psychiatric disor-
ders, a consensus on the role of the DISC1 gene has not yet been 
reached. Here, we identified that the pattern of cortical thinning, 
but not rCBF, cortical surface area, or subcortical volumes, is a 
robust phenotype for translocation at DISC1. The pattern of cor-
tical thinning is also highly similar to that observed in patients 
diagnosed with SCZ. The biological roles of DISC1 fit well with 
our current knowledge on the etiological roots of SCZ. Our data 
suggests that the t(1:11) translocation in this pedigree could 
increase the risk of psychiatric disorders including SCZ through 
affecting neurostructural phenotypes such as cortical thickness.
Figure 2. Prediction of belonging to the SCZ group across modalities. Contingency table 
for the family groups with and without the translocation (T+ and T–, respectively) tested 
using a classifier trained to discriminate between HC and patients diagnosed with SCZ. The 
rows represent the ground truth, i.e., T+ or T–, and the columns represent the predictions 
made by the model in relation to the HC versus SCZ contrast.
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Preprocessing. All scans were anonymized at the time of acquisi-
tion. Image preprocessing followed a set protocol, and the analysis 
protocol was strictly adhered to regardless of the genetic or clinical 
status of the participant. Structural images were processed using Free-
Surfer v5.3 (http://surfer.nmr.mgh.harvard.edu/). Volumetric seg-
mentation, cortical surface reconstruction, and cortical parcellation 
were used to quantify the thickness and surface areas of cortical ana-
tomical regions. Cortical anatomical regions were defined by the Desi-
kan-Killiany atlas (47). Subcortical volumes were defined as by Fischl 
and colleagues (48). Cortical surface area and the subcortical volumes 
were normalized by the total intracranial volume for each subject (49).
Perfusion images were preprocessed using ASLtbx (50). Briefly, 
motion correction was performed on the perfusion time series using 
6-parameter rigid body spatial transformation. The perfusion images 
were then coregistered to each subject’s structural image. The images 
were then smoothed using a Gaussian kernel, and a brain mask was 
generated. CBF quantification was performed to produce a mean 
CBF image per subject. The CBF maps were then spatially normal-
ized into a standard space using the MNI 125 averaged brain template. 
Full brain coverage was not acquired for each subject; therefore, after 
preprocessing, a consensus mask of voxels was created and applied to 
all images so that the same number of voxels was considered for each 
subject. Each image was scaled by the mean across all voxels.
Multivariate pattern classification. Multivariate pattern classification 
can be used to discriminate between groups of subjects by modeling the 
spatial pattern of brain changes (51, 52). This is particularly advanta-
geous for detecting neurobiological changes associated with psychiat-
ric disorders, which are often subtle and widespread across the brain, 
i.e., inherently multivariate. Moreover, the classifier can be trained to 
distinguish between HC and SCZ and then used to assign a probability 
of belonging to the SCZ group for independent participant data. This 
reflects how similar the underlying pattern of neurobiology for the 
T– and T+ groups is to that of either SCZ or HC. To assess the specificity 
of the HC versus SCZ model, we used the BP group as a test set.
Classification aims to learn the mapping between a multivariate 
data source (e.g., cortical thickness) and a label of interest (+1 or –1; 
e.g., belonging to the T+ or T– group) in order to predict the label for 
a new participant. An important consideration for these approaches 
is “overfitting,” whereby the model is overly complex and does not 
generalize well to new, unseen data. To help alleviate this, we used 
Figure 3. P(SCZ) from the cortical thickness classifier for the family cohort and the mean cortical thickness. (A) Mean cortical thickness plotted 
against P(SCZ) with the translocation carriers displayed in dark blue and the translocation noncarriers displayed in light blue. (B) The translocation 
carrier group displayed on an individual basis in terms of clinical diagnosis, P(SCZ), and mean cortical thickness. Conduct disorder (Ads), conduct 
disorder diagnosed as an adolescent.
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approaches that incorporate regularization that penalizes model 
complexity. Moreover, pattern recognition was performed using 
crossvalidation whereby a portion of the data was preserved for 
independently testing the model.
We employed Gaussian process classification (GPC) imple-
mented in a Bayesian framework. GPC has been well validated in 
the neuroimaging community across a wide range of applications, 
including psychiatry (53–56) and neurology (57–59). We focused 
on this approach rather than the commonly used support vec-
tor machines (60), as GPC provides similar performance and also 
probabilistic estimates of class membership quantifying the uncer-
tainty of the individual predictions. For a detailed overview of this 
approach, we refer the reader to Rasmussen and Williams (61). GPC 
was implemented using a linear model within the GPML v3.1 toolbox 
(http://www.gaussianprocess.org/gpml/code/matlab/doc/) (62).
Classification was performed to answer the following questions: 
(a) how similar are those in the T+ group to those in the SCZ group in 
terms of their brain-related phenotype (see Figure 4A), and (b) do the 
T+ group members have a distinct brain-related phenotype in com-
parison with those in the T– group (see Figure 4B)? First, we developed 
a model that discriminates between the HC and SCZ groups. To pre-
vent nuisance covariates from driving the classification, we ensured 
that the training groups were matched for age and sex. We assumed 
that test samples were independent and therefore matching across 
test groups was not required. Nonetheless, the ages of the test samples 
were in the same range as the ages of the training sample, and covary-
ing for age across training and test data did not alter the findings we 
present. The model was trained using pairwise leave-one-out cross-
validation (pLOOCV) on the HC versus SCZ data whereby all but 1 pair 
of matched subjects’ data were used to train the model and the pair 
of subjects left out was used as the test case; this process was iterated 
until each pair of subjects had served as a test case.
To assess whether the classification accuracy for a particular con-
trast was significantly greater than chance (50%), we used permuta-
tion testing. To achieve this, the training labels used for classification 
were shuffled (permuted), the classifier was trained using these per-
muted labels, and then the trained model was applied to the test data. 
The accuracy of the classifier in detecting the true test labels based on 
permuted labels is known as the permuted accuracy. The procedure of 
permuting the training labels was repeated 1,000 times to produce the 
null distribution of accuracies. We then counted the number of times 
that the permuted accuracy was greater than that obtained using the 
true training labels. This count was divided by the number of permu-
tations (1,000) to estimate a P value for the classification accuracies.
When statistically significant, the model was trained on all of the 
HC versus SCZ data and tested on the translocation groups to provide 
a prediction of which group (HC or SCZ) the data from the family 
(T+ and T-) are most similar to. To assess whether the predictions for 
the T+ and T– groups were significantly different from chance, we 
used Fisher’s exact test. We expected the T– cases to belong to the HC 
group and the T+ cases to belong to the SCZ group. As stated above, 
it was crucial to match the training data for nuisance covariates and 
then assume that the test data were drawn from the same range. None-
theless, to robustly assess the effect of age, the correlation (Pearson’s 
Figure 4. Pipeline for the 2 machine-learning schemes used in this work. (A) The classifier is trained to discriminate between HC and patients diagnosed with 
SCZ (matched for age and sex). The trained classifier is then tested on the members of the Scottish family who do not carry the translocation (T–) and those that 
do carry the translocation (T+). (B) The classifier is trained in LOOCV to discriminate between age- and sex-matched participants from the T–ʹ and T+ groups.
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correlation) between predictive probabilities of belonging to the SCZ 
group with the age of the family members was computed. For the fam-
ily, we also assessed the correlation between the predictive probabili-
ties of belonging to the SCZ group and the PANSS General Psychopa-
thology scale. As the sample size investigated here is modest, we used 
the Cook distance measure to assess whether potential correlations 
were driven by outliers in the data (36). We excluded 3 subjects with a 
Cook distance greater than 0.5 (63). If subjects reached the exclusion 
threshold, they were removed and the correlations were recalculated.
Second, the model was trained on the T– versus T+ data directly 
using LOOCV (see Figure 4B). As the family data were now used 
to train the model, the T– group was downsampled to match the T+ 
group for age and sex; we refer to this group as T–ʹ. The LOOCV pro-
cedure was implemented rather than pLOOCV, as the T+ and T–ʹ 
groups were not equally sized and hence the paired approach was 
not appropriate. To assess the relationship between the certainty of 
the predictions and the dose of medication, we tested the correla-
tion (Pearson’s correlation) between the predictive probabilities of 
belonging to SCZ group and the dose of antipsychotic medication. 
To visualize the pattern of brain regions driving the discriminative 
model, we mapped the multivariate weight patterns. These weight 
patterns are sensitive to the spatial covariance in the data; there-
fore, we avoided performing local statistical inference and instead 
considered the pattern. Note that the weights extracted from the 
Gaussian process classifier do not correspond directly to magnitude 
changes across groups, as they are influenced by additional factors 
such as variance and covariance.
Statistics. Permutation testing was used to compute the P value 
for a particular classification accuracy. To investigate the linear rela-
tionship between variables, Pearson’s product-moment correlation 
coefficient was computed and the associated P value was assessed for 
significance. The Wilcoxon signed-rank test was used to assess differ-
ences in cortical thickness across groups. In all cases, P values of less 
than 0.05 were considered significant.
Study approval. This study was approved by the Multi-Centre 
Research Ethics Committee in Scotland. All study participants gave 
their written, informed consent.
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